Navigation Links
K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment
Date:10/20/2010

ST. LOUIS, Oct. 20 /PRNewswire-FirstCall/ -- K-V Pharmaceutical Company (NYSE:  KVa/KVb) today announced the establishment of a new generic marketing subsidiary, Nesher Pharmaceuticals, Inc. and the appointment of Mark Hartman as its President.

Greg Divis, Interim President and Chief Executive Officer of the Company, stated, "Mark brings recognized depth and breadth of generic industry experience and leadership to K-V.  We are excited to have Mark join our organization and look forward to him leading the introduction of Nesher Pharmaceuticals, Inc., K-V's new generic subsidiary.  After recently receiving Food and Drug Administration ("FDA") approval to return the first of our generic products to the market, Mark will be spearheading our 'go to market' strategy and subsequent product launch efforts.  We remain focused on returning additional generic products to the market while also preparing for upcoming product launches at Ther-Rx Corporation, our branded marketing subsidiary."

Mr. Divis continued, "A key business objective remains for K-V to maximize the value of our generic business in alignment with our long-term strategy.  We believe that the addition of Mark to our team coupled with the introduction of Nesher Pharmaceuticals, Inc. provides K-V with flexibility and capability to execute on this business priority."

Mark Hartman

Mr. Hartman is a seasoned executive healthcare professional with extensive sales, marketing and management experience in the generic pharmaceutical industry.  He has achieved significant accomplishments in building and leading high performing businesses, developing and executing product launch plans, and attracting and retaining top talent with a proven track record of growing businesses.

Mark has held senior leadership positions at well-known companies in the pharmaceutical industry including, President, North America Operations for Wockhardt USA, LL
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 Inovio Pharmaceuticals, Inc. ... a conference call to report its second quarter 2014 ... AM ET. CEO Dr. J. Joseph Kim ... quarter earnings, provide a corporate update, and participate in ... clinical development plans for VGX-3100, Inovio,s immune therapy targeting ...
(Date:8/1/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Tricalcium ... Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... Global and China Potassium Nitrate  Industry" is a ... China and Global Potassium Nitrate  market. ...
(Date:7/31/2014)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) ... Chief Business Officer and Executive Vice President. Mr. Singh died ... "Sorrento is deeply saddened and shocked by the ... go to Amar,s family and friends," said Henry Ji ... Mr. Singh joined Sorrento in January 2014 from Synta ...
Breaking Medicine Technology:Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... Society for Biomolecular Sciences Conference, THE WOODLANDS, ... Incorporated announced that data was presented,today highlighting ... Genentech, Inc. at the Society for Biomolecular,Sciences ... These target discoveries were made in a ...
... BASKING RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ ... company focused on acquiring, developing and,commercializing targeted ... of VQD- 002, a direct inhibitor of ... hematologic tumors.,Pre-clinical data was presented in a ...
Cached Medicine Technology:Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 2Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 3Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 4Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 5VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:8/1/2014)... August 01, 2014 The evolving ... independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and ... with practices and resources to enhance patient care ... focused on critical issues to give independent pharmacists ... grow. , ThoughtSpot show attendance experienced a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, medical ... boosting healthcare market growth, although a reduction in ... generic consumption is a major challenge. , Turkey’s ... having grown at a Compound Annual Growth Rate ... the Health Transformation Program (Saglikta Donus, um Programi, ...
(Date:8/1/2014)... (HealthDay News) -- Patients with the progressive, deadly respiratory ... a new weapon to battle the disease, the U.S. ... agency approved a new treatment, an inhaled spray called ... of Americans. COPD, which is often linked to smoking, ... emphysema. Patients with COPD may experience a ...
(Date:8/1/2014)... August 01, 2014 For years, proponents ... A recent study conducted by the Ohio ... too far behind in terms of their health and ... know what’s best for their baby. So does this ... Dr. Steven Shapiro , chair of Pediatrics at ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Oxford ... company develops biomarkers. Its products include CytoSure heamatological ... +SNP Array, CytoSure ISCA UPD array, CytoSure ISCA ... array. OGT offers services, such as targeted sequencing ... service, miRNA analysis, gene expression analysis, cytosure services ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... ... ... ... ...
... The U.S. ,race gap, in the commission of violent crime ... arrest rates for African Americans out-distancing those for whites concludes ... University and the University of Oregon. While the gap ... grew again in the ,80s with the advent of crack cocaine. ...
... ... of the New England ADHD Treatment Center are excited to announce a new five week ... ... and Dr. Jeffrey Speller of the New England ADHD Treatment Center are excited to ...
... ... “ADDY” Awards at the 2010 ADDY Awards Ceremony presented in Akron, ... program is the largest advertising competition in the world. With over ... arguably toughest advertising competition. The ADDY Awards represents the true spirit ...
... ... ... , ... , ...
... the rate of growth of the cancer tumour. The standard ... This is the conclusion of scientists at the University of ... The principal reason that patients die of cancer is the ... tumours known as metastases. These metastases are initially so small ...
Cached Medicine News:Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 2Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 3Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 4Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 5Health News:Violent crime 'race gap' narrows, but persists in US 2Health News:Violent crime 'race gap' narrows, but persists in US 3Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 2Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 3Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 2Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 3Health News:Special Session Highlights Late-Breaking Abstracts 2Health News:Special Session Highlights Late-Breaking Abstracts 3Health News:Special Session Highlights Late-Breaking Abstracts 4Health News:Special Session Highlights Late-Breaking Abstracts 5
... The wrap frame is constructed of ... while minimizing potential breakage. The molded ... a full saddle bridge to distribute weight ... peripheral vision with leaded glass side shields. ...
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... frames are designed with the safety and comfort ... Schott RS-520 (also called SF-6) leaded glass, the ... meet standards, as set for optical clarity, visible ... our eyewear is protecting your eyes, it also ...
Medicine Products: